NEW YORK, July 30, 2026
DarioHealth Corp. has unveiled its Integrated GLP-1 Program, a comprehensive healthcare solution that combines AI-powered chronic disease management with provider-backed clinical care in a single end-to-end platform. The launch represents the first commercial offering resulting from Dario’s strategic collaboration with Beluga Health, integrating licensed healthcare provider evaluations, prescribing of FDA-approved GLP-1 medications where clinically appropriate, and continuous medical oversight directly into Dario’s existing digital chronic care ecosystem. Expected to become commercially available in Fall 2026, the new platform is projected to begin contributing revenue in late 2026 with broader commercial expansion throughout 2027. The integrated solution addresses the rapidly evolving healthcare landscape where employers and health plans are tightening GLP-1 reimbursement policies, while patients increasingly seek convenient consumer-based healthcare services that combine digital engagement with professional clinical support.
Integrated Digital and Clinical Care Enhances GLP-1 Therapy Management
The newly launched Integrated GLP-1 Program transforms the traditional patient experience by combining medical evaluation, personalized prescribing, AI-powered monitoring, nutrition guidance, behavioral coaching, and ongoing clinical oversight within one unified platform. Unlike conventional digital health programs that support patients after receiving prescriptions elsewhere, Dario’s solution provides the complete care pathway under one roof. Through Beluga Health’s network of licensed healthcare providers, eligible patients can receive comprehensive medical evaluations and, when clinically appropriate, prescriptions for FDA-approved GLP-1 medications while continuing to benefit from Dario’s AI-driven chronic care management tools. The integrated model is designed to improve long-term treatment adherence, optimize clinical outcomes, and simplify patient access to obesity and chronic disease care. By merging digital health technology with continuous provider engagement, Dario aims to create a more connected healthcare experience that supports patients throughout every stage of their treatment journey.
Three Commercial Channels Expand Access to GLP-1 Care
Dario plans to make the Integrated GLP-1 Program available through three primary commercial channels to maximize patient access. The first channel will launch through the MyDario Shop, the company’s direct-to-consumer marketplace that has served more than one million consumers over the past three years. The second channel targets health plan marketplaces, offering insurers a clinically managed GLP-1 pathway that supports responsible prescribing and chronic disease management while helping control healthcare costs. The third channel expands Dario’s existing employer B2B2C programs, allowing organizations to provide employees with integrated obesity management services backed by cardiometabolic care programs and optional prescription savings initiatives. Across all three channels, anonymized member interactions and clinical data will feed the company’s DarioIQ™ AI engine, enabling continuous optimization of treatment recommendations, patient engagement strategies, and healthcare cost savings for employers and health plans.
Advertisement
AI-Driven Healthcare Supports Growing Demand for Chronic Care Solutions
The launch comes as demand for GLP-1 therapies continues to reshape obesity and chronic disease management worldwide. As employers and health plans move toward more clinically managed reimbursement models, Dario’s integrated platform is positioned to support evidence-based prescribing while improving long-term patient outcomes. Powered by more than 13 billion proprietary longitudinal healthcare data points, Dario’s AI platform analyzes biometric, behavioral, and clinical information to deliver personalized interventions across conditions including diabetes, hypertension, obesity, musculoskeletal disorders, and behavioral health. The company’s integrated approach reflects the growing convergence of artificial intelligence, digital therapeutics, remote monitoring, and provider-led care, creating a scalable healthcare model capable of addressing multiple chronic diseases through a single technology platform. By combining clinical expertise with AI-driven engagement, Dario aims to improve treatment effectiveness while reducing overall healthcare costs for patients, employers, and health systems.
Source: DarioHealth press release
